Evidence map›Paper›PMID 29328866›Full record

ReviewThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society2018

Proteoglycans as Immunomodulators of the Innate Immune Response to Lung Infection.

Inkyung Kang, Mary Y Chang, Thomas N Wight, Charles W Frevert

Open access · hybridAbstract readReview
In one paragraph

Review in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Biomimetic strategies for the deputization of proteoglycan functions.Frontiers in cell and developmental biology · 2024
    Review
  11. V3: an enigmatic isoform of the proteoglycan versican.American journal of physiology. Cell physiology · 2023
    Review
  12. Innate immune responses in pneumonia.Pneumonia (Nathan Qld.) · 2023
    Review
  13. Defining the versican interactome in lung health and disease.American journal of physiology. Cell physiology · 2022
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Type I Interferon Signaling Increases Versican Expression and Synthesis in Lung Stromal Cells During Influenza Infection.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Inkyung KangMatrix Biology Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington.
Mary Y ChangComparative Pathology Program, Department of Comparative Medicine, University of Washington School of Medicine, Seattle, Washington.
Thomas N WightMatrix Biology Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington.
Charles W FrevertCenter for Lung Biology, Division of Pulmonary/Critical Care Medicine, University of Washington School of Medicine, Seattle, Washington.
University of Washington · USVirginia Mason Medical Center · US

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4M
Regulation of the Innate Immune Response by the Epithelium in AsthmaU19AI125378 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI CAMPBELL, DANIEL J · 2016 to 2020
$9.2M
Impact of versican deficiency on the innate immune response to influenza virusR01AI136468 · NIAID · UNIVERSITY OF WASHINGTON · PI ALTEMEIER, WILLIAM A, FREVERT, CHARLES WAYNE · 2018 to 2022
$3.1M
NIAID NIH HHS R01 AI136468NIAID NIH HHS U19 AI125378NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

Proteoglycans (PGs) are complex, multifaceted molecules that participate in diverse interactions vital for physiological and pathological processes. As structural components, they provide a scaffold for cells and structural organization that helps define tissue architecture. Through interactions with water, PGs enable molecular and cellular movement through tissues. Through selective ionic interactions with growth factors, chemokines, cytokines, and proteases, PGs facilitate the ability of these soluble ligands to regulate intracellular signaling events and to influence the inflammatory response. In addition, recent findings now demonstrate that PGs can activate danger-associated molecular patterns (DAMPs) and other signaling pathways to influence production of many of these soluble ligands, indicating a more direct role for PGs in influencing the immune response and tissue inflammation. This review will focus on PGs that are selectively expressed during lung inflammation and will examine the novel emerging concept of PGs as immunomodulatory regulators of the innate immune responses in lungs.

Indexed as

Immunity, InnateAnimalsCommunicable DiseasesExtracellular MatrixHumansImmunomodulationLungPneumoniaProteoglycansSignal TransductionProteoglycansextracellular matrixinnate immunitypulmonary inflammationversican

Identifiers

PMID29328866
PMCPMC5958380
OpenAlexW2784135059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.